ERBB2 and alveolar rhabdomyosarcoma: The results reported here demonstrate high and specific activity of NK-92/5.28.z cells against ERBB2-positive aRMS cells, justifying further efforts to develop these cells as a novel treatment approach for high-risk RMS patients.